Ligand Pharmaceuticals Management
Management criteria checks 3/4
Ligand Pharmaceuticals' CEO is Todd Davis, appointed in Dec 2022, has a tenure of 1.92 years. total yearly compensation is $6.22M, comprised of 10.5% salary and 89.5% bonuses, including company stock and options. directly owns 0.42% of the company’s shares, worth $8.86M. The average tenure of the management team and the board of directors is 2 years and 15 years respectively.
Key information
Todd Davis
Chief executive officer
US$6.2m
Total compensation
| CEO salary percentage | 10.5% |
| CEO tenure | 1.9yrs |
| CEO ownership | 0.4% |
| Management average tenure | 2yrs |
| Board average tenure | 15yrs |
Recent management updates
Recent updates
Market Participants Recognise Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Earnings
Oct 31
Ligand Pharmaceuticals: Solid Performer Performing Solidly
Jul 29Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected
Jul 18Should You Be Adding Ligand Pharmaceuticals (NASDAQ:LGND) To Your Watchlist Today?
Jun 29Subdued Growth No Barrier To Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) With Shares Advancing 27%
May 23Ligand: Buy This Pharma Royalty Aggregator To Generate Growth In Your Portfolio
Apr 30Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Not Flying Under The Radar
Dec 19Is Now The Time To Put Ligand Pharmaceuticals (NASDAQ:LGND) On Your Watchlist?
Jun 14We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt
May 29Are Investors Undervaluing Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) By 45%?
May 07These 4 Measures Indicate That Ligand Pharmaceuticals (NASDAQ:LGND) Is Using Debt Reasonably Well
Jan 26We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt
Oct 21Ligand Pharmaceuticals: Struggling Along
Sep 25Growth Investors: Industry Analysts Just Upgraded Their Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Revenue Forecasts By 11%
Aug 11Here's Why Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt Responsibly
Jun 27Ligand Pharmaceuticals: Moving Parts Keep Moving
Mar 29CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$45m |
| Jun 30 2024 | n/a | n/a | US$42m |
| Mar 31 2024 | n/a | n/a | US$96m |
| Dec 31 2023 | US$6m | US$650k | US$54m |
| Sep 30 2023 | n/a | n/a | US$21m |
| Jun 30 2023 | n/a | n/a | US$41m |
| Mar 31 2023 | n/a | n/a | US$51m |
| Dec 31 2022 | US$6m | US$49k | -US$5m |
| Sep 30 2022 | n/a | n/a | US$23m |
| Jun 30 2022 | n/a | n/a | US$27m |
| Mar 31 2022 | n/a | n/a | US$45m |
| Dec 31 2021 | US$328k | n/a | US$76m |
| Sep 30 2021 | n/a | n/a | US$68m |
| Jun 30 2021 | n/a | n/a | US$48m |
| Mar 31 2021 | n/a | n/a | US$39m |
| Dec 31 2020 | US$329k | n/a | US$7m |
| Sep 30 2020 | n/a | n/a | -US$16m |
| Jun 30 2020 | n/a | n/a | -US$25m |
| Mar 31 2020 | n/a | n/a | -US$61m |
| Dec 31 2019 | US$350k | n/a | US$629m |
| Sep 30 2019 | n/a | n/a | US$594m |
| Jun 30 2019 | n/a | n/a | US$677m |
| Mar 31 2019 | n/a | n/a | US$764m |
| Dec 31 2018 | US$343k | n/a | US$143m |
| Sep 30 2018 | n/a | n/a | US$179m |
| Jun 30 2018 | n/a | n/a | US$120m |
| Mar 31 2018 | n/a | n/a | US$53m |
| Dec 31 2017 | US$283k | n/a | US$13m |
Compensation vs Market: Todd's total compensation ($USD6.22M) is about average for companies of similar size in the US market ($USD5.35M).
Compensation vs Earnings: Todd's compensation has been consistent with company performance over the past year.
CEO
Todd Davis (63 yo)
1.9yrs
Tenure
US$6,216,518
Compensation
Mr. Todd C. Davis, Ph.D. is a Director at NVN Liquidation Inc. He serves as an Independent Director of Channel Therapeutics Corporation (formerly known as Chromocell Therapeutics Corporation) since January...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.9yrs | US$6.22m | 0.42% $ 8.9m | |
| Chief Financial Officer | 2yrs | US$2.45m | 0.13% $ 2.8m | |
| Chief Legal Officer & Secretary | 2yrs | US$2.34m | 0.12% $ 2.5m | |
| Senior Vice President of Investments & Business Development | no data | no data | no data | |
| Head of Investor Relations | no data | no data | no data | |
| Director of Corporate Development | no data | no data | no data | |
| Senior Vice President of Biology & Scientific Affairs | 6.8yrs | no data | no data | |
| Senior Vice President of Technical Operations & QA - Capitsol | 6.8yrs | no data | no data | |
| Senior VP & CBO Protein Expression Business | no data | no data | no data | |
| Senior VP of Investments & Head of Clinical Strategy | less than a year | no data | no data | |
| Senior VP of Investment Operation | less than a year | no data | no data | |
| CEO of Pelthos Therapeutics | less than a year | no data | no data |
2.0yrs
Average Tenure
57yo
Average Age
Experienced Management: LGND's management team is not considered experienced ( 2 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 17.7yrs | US$6.22m | 0.42% $ 8.9m | |
| Independent Chairman | 21.7yrs | US$361.70k | 0.23% $ 4.8m | |
| Independent Director | 13.8yrs | US$329.20k | 0.15% $ 3.2m | |
| Independent Director | 16.3yrs | US$341.70k | 0.15% $ 3.2m | |
| Independent Director | 18.2yrs | US$339.20k | 0.43% $ 9.2m | |
| Scientific Advisor | no data | no data | no data | |
| Independent Director | 2.4yrs | US$346.70k | 0.022% $ 463.5k | |
| Independent Director | 7.3yrs | US$336.70k | 0.030% $ 629.7k | |
| Independent Director | 1.2yrs | US$467.87k | no data |
15.0yrs
Average Tenure
63.5yo
Average Age
Experienced Board: LGND's board of directors are seasoned and experienced ( 15 years average tenure).